Background
==========

*Mycoplasma hominis* is a small free-living organism belonging to the genus *Mycoplasma* \[[@b1-amjcaserep-20-406]\]. *Mycoplasma* lacks a rigid cell wall and therefore cannot be visualized by routine light microscopy \[[@b1-amjcaserep-20-406]\]. Moreover, the lack of a cell wall prevents visualization of *Mycoplasma* species by Gram staining and makes the organism resistant to cell wall inhibitors such as beta-lactam antibiotics \[[@b1-amjcaserep-20-406]--[@b3-amjcaserep-20-406]\]. It is very challenging and resource- and time-consuming to diagnose infections caused by this organism because of the requirement for special selective medium and specific incubation conditions for culturing *M. hominis* \[[@b4-amjcaserep-20-406]\]. Furthermore, there are few biochemical traits that are valuable for diagnosis \[[@b4-amjcaserep-20-406]\]. Accordingly, matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) has been adopted as a cost-effective, rapid, reliable method for the diagnosis of *M. hominis* \[[@b5-amjcaserep-20-406]\].

*M. hominis* generally colonizes the urogenital tracts of sexually active adults and is a causative organism of urogenital tract infections \[[@b1-amjcaserep-20-406]\]. Central nervous system (CNS) infections due to *M. hominis* are rare. To best of our knowledge, only 21 cases of CNS infection caused by *M. hominis*, including our current case, have been reported in the literature.

Here, we present a successfully treated case of *M. hominis* ventriculitis secondary to extraventricular drain. This is the first case of *M. hominis* causing CNS infection reported in a country in the Middle East.

Case Report
===========

A 25-year-old man was admitted to the emergency room as a victim of a motor vehicle crash. His Glasgow coma score was 8/15, and he was therefore electively intubated and attached to mechanical ventilation. Whole-body computed tomography (CT) was performed, yielding the following findings: CT of the spine showed a nondisplaced compression fracture at the ninth and 10^th^ thoracic vertebrae; CT of the chest showed bilateral basal atelectasis/consolidation likely related to aspiration, with bilateral ground-glass opacities and nondisplaced manubrium sternal fracture; CT of the abdomen showed a small (0.5 cm) contusion over the spleen; CT of the head showed an acute left subdural hemorrhage with underlying mild brain edema and a right midline shift of approximately 1 cm.

Based on these findings, emergency decompressive craniectomy with extraventricular drain (EVD) insertion was performed. He was then admitted to the surgical intensive care unit (SICU) and maintained on mechanical ventilation. On day 5, he developed fever with leukocytosis; septic workup, including cerebral spinal fluid (CSF) analysis and culture, indicated EVD-related ventriculitis, and the patient was administered vancomycin and meropenem. However, the antibiotic regimen was adjusted based on culture results ([Table 1](#t1-amjcaserep-20-406){ref-type="table"}), and the patient received a full course of lipid-formulated amphotericin B and vancomycin (for *Candida albicans* and *Staphylococcus hemolyticus*).

After 8 days, the EVD was removed. Four days later, he developed deterioration of consciousness, and a new CT scan of the brain showed active hydrocephalus ([Figure 1](#f1-amjcaserep-20-406){ref-type="fig"}) with a worsening midline shift. Hence, another EVD was inserted, and a full septic workup was performed ([Table 1](#t1-amjcaserep-20-406){ref-type="table"}).

On day 18, he underwent debridement at the cephalic surgical site, and a full course of ceftazidime was administered owing to wound infection. On day 25, the patient underwent tracheostomy placement. Postoperatively, he became febrile, and his Glasgow coma scale remained at 8/15. Leukocytosis (14.3 k/µL) was also observed, and another septic screening was performed; the results of CSF culture revealed *M. hominis* ([Table 1](#t1-amjcaserep-20-406){ref-type="table"}). The same isolate regrew from a confirmatory sample on day 28. The next day, the second EVD was changed, and he was administered intravenous ciprofloxacin 400 mg every 8 h for a total duration of 14 days. On day 39, the patient was clinically improved and transferred to the general ward. The third EVD remained in place until day 45. He was maintained on nasogastric feeding and tracheostomy. A few days later, he was transferred to another health care facility upon his employer's request. The patient did not follow up with our facility after that.

Microbiology laboratory findings
--------------------------------

Yellowish clear CSF samples from EVD were inoculated on sheep blood agar, MacConkey agar, chocolate agar, anaerobic blood agar, and thioglycolate broth, incubated at 37°C according to the internal policies and procedures of the microbiology laboratory at King Fahd Hospital of the University. CSF analysis revealed a white blood cell count of 1430/cu mm, with 82% segmented cells, a protein value of 316 mg/dL, and a glucose level of 3.0 mg/dL. Direct Gram stain smears from samples showed few pus cells and no organisms. After 48 h of incubation, there was growth of nonhemolytic, translucent, pinpoint colonies on anaerobic blood agar only ([Figure 2](#f2-amjcaserep-20-406){ref-type="fig"}). Gram stain smears from colonies showed no evidence of bacteria. The isolate was identified as *M. hominis* using MALDI-TOFMS (VITEK MS; bioMérieux) and Knowledge Base database (version 3.0), with a confidence value of 99.9. Subsequent CSF samples also grew colonies of *M. hominis*. [Table 1](#t1-amjcaserep-20-406){ref-type="table"} summarizes CSF laboratory results for the patient during admission.

Discussion
==========

*M. hominis* primarily colonizes the respiratory tract and genitourinary tract. This organism is mainly transmitted to humans through obstruction of the urinary tract, sexual contact, and vertical transmission in utero or intrapartum \[[@b1-amjcaserep-20-406],[@b3-amjcaserep-20-406]\]. Surface antigenic variation of *M. hominis* may be related to the persistence of these organisms at invasive sites \[[@b1-amjcaserep-20-406]\]. Most infections caused by *M. hominis* are primarily related to genital tract colonization.

The infections caused by this organism include acute pyelonephritis, cervicitis, endometritis, tubal factor infertility, postabortion bacteremia, bacterial vaginosis, and other genital tract infections. Other reportable clinical conditions caused by *M. hominis* include bacteremia after renal transplantation, trauma, and genitourinary manipulations; osteomyelitis; septic arthritis; aspiration associated-empyema; peritonitis; intra-abdominal abscesses; and wound infections \[[@b1-amjcaserep-20-406],[@b3-amjcaserep-20-406]\]. In the early 1980s, *M. hominis* infections were also reported following organ transplantation and immunosuppressive therapy. These infections most likely originated from the patient's normal flora \[[@b4-amjcaserep-20-406]\].

*M. hominis* has also been reported from brain abscesses and meningitis. Several cases of CNS infection by *M. hominis* have been described in premature infants with prolonged rupture of the membranes, probably owing to genital colonization of pregnant women. These neonates usually present with mild, subclinical meningitis without sequelae or neurological damage with permanent handicaps \[[@b1-amjcaserep-20-406],[@b3-amjcaserep-20-406]\]. In adults, rare cases of *M. hominis* meningitis have been described mainly following neurosurgery manipulations \[[@b3-amjcaserep-20-406],[@b6-amjcaserep-20-406],[@b7-amjcaserep-20-406]\]. Moreover, few cases of *M. hominis* infection following ventriculoperitoneal shunt insertion with central nervous system involvement have been reported \[[@b7-amjcaserep-20-406],[@b8-amjcaserep-20-406]\]. In general, CNS infections with *M. hominis* usually resolve spontaneously \[[@b3-amjcaserep-20-406]\]. Existing literature on patients with CNS infection caused by *M. hominis* is summarized in [Table 2](#t2-amjcaserep-20-406){ref-type="table"}.

Isolation of *M. hominis* in any quantity from sterile body fluids is significantly associated with disease, and identification at the species level is necessary \[[@b1-amjcaserep-20-406]\]. The optimal temperature for *M. hominis* growth is between 35 and 37°C, and these organisms grow best under anaerobic conditions, usually within 1--5 days of incubation \[[@b3-amjcaserep-20-406]\]. *M. hominis* can be detected routinely in bacteriologic culture medium, such as chocolate agar or blood agar; accordingly, there have been many instances of incidental discovery when *Mycoplasma* species were not specifically sought \[[@b3-amjcaserep-20-406]\]. MALDI-TOF MS is a rapid, reliable, cost-effective method and has been shown to accurately identify most *Mycoplasma* species, particularly *M. hominis* \[[@b1-amjcaserep-20-406],[@b5-amjcaserep-20-406]\].

*Mycoplasma* species are innately resistant to all beta-lactams, sulfonamides, trimethoprim, and rifampin. *M. hominis* is usually susceptible to tetracycline, fluoroquinolone, clindamycin, chloramphenicol, streptomycin, and gentamicin \[[@b1-amjcaserep-20-406],[@b3-amjcaserep-20-406]\]. Some strains of *M. hominis* have been reported to be resistant erythromycin, fluoroquinolone, and tetracycline. The extent to which tetracycline resistance occurs in *M. hominis* varies geographically and may reach 40--50% in some locations. Agar dilution is considered the reference method for antimicrobial testing for *Mycoplasma* \[[@b1-amjcaserep-20-406]\].

Conclusions
===========

The findings of this case report, coupled with a thorough review of the literature, demonstrated the pathogenic potential of *M. hominis*. Particularly in developing countries, in which laboratories may have limited access to advanced technologies, such rare infectious diseases remain major diagnostic challenges.
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###### 

CSF results of the patient during admission.

  **Day of shunting**   **WBC (cu/mm)**   **% Segmented**   **% Lymphocytes**   **Protein (mg/dL)**   **Glucose (mg/dL)**   **Culture**
  --------------------- ----------------- ----------------- ------------------- --------------------- --------------------- ----------------------------------------------------
  Day 5                 NA                NA                NA                  NA                    113                   *Candida albicans* & *Staphylococcus haemolyticus*
  Day 11                14                36                59                  27.4                  55                    *Candida albicans*
  Day 15                100               83                11                  266.4                 45                    No growth
  Day 17                135               81                14                  410.8                 49                    No growth
  Day 21                130               85                10                  NA                    NA                    No growth
  Day 25                1430              82                6                   316.0                 3                     *Mycoplasma hominis*
  Day 28                210               31                49                  327.2                 32                    *Mycoplasma hominis*
  Day 33                1892              40                53                  176                   33                    No growth
  Day 38                19                34                59                  151.7                 55                    No growth
  Day 39                315               20                78                  149.3                 43                    No growth
  Day 47                335               54                21                  135.5                 78                    No growth
  Day 52                25                8                 79                  152.5                 55                    No growth
  Day 57                35                55                23                  139.4                 68                    No growth

###### 

Summary of the reported cases of CNS infection caused by *Mycoplasma hominis* (1950--2018).

  **Case N**   **Author \[reference\]**                                       **Age/sex**   **Presentation**                                                                                   **Treatment**                                                                                                                                                                                          **Duration of treatment**       **Outcome**
  ------------ -------------------------------------------------------------- ------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------- --------------------------------
  1            Our case                                                       25/Male       Fever and leukocytosis post EVD                                                                    Ciprofloxacin 400 milligrams every 8 hours                                                                                                                                                             14 days                         NED
  2            Sato M et al. (2017) \[[@b8-amjcaserep-20-406]\]               6/Female      Fever post ventriculoperitoneal shunt (VPS)                                                        VPS Replacement and Ciprofloxacin 10 mg/kg every 12 hours plus clindamycin 13 mg/kg every 8 hours                                                                                                      6 weeks                         NED
  3            Zhou M et al. (2016) \[[@b6-amjcaserep-20-406]\]               71/Male       fever, anepia and right-sided weakness                                                             azithromycin 0.5 g qd and minocycline 100 mg q12h                                                                                                                                                      2 weeks                         NED
  4            Reissier S et al. (2016) \[[@b9-amjcaserep-20-406]\]           39/Male       Fever, loss of consciousness                                                                       Meropenem, vancomycin and moxifloxacin                                                                                                                                                                 Day 34 to day 49 of admission   Death at day 80 of admission
  5            Hos N et al. (2015) \[[@b10-amjcaserep-20-406]\]               21/Female     Fever, neck pain, nausea, vomiting,                                                                Oral moxifloxacin at a daily dose of 400 mg                                                                                                                                                            4 weeks                         NED
  6            Whitson W et al. (2014) \[[@b11-amjcaserep-20-406]\]           17/Male       Fever, bicep and deltoid weakness                                                                  Initial with vancomycin, moxifloxacin, and doxycycline then changed to intravenous moxifloxacin finally to oral moxifloxacin                                                                           6 months                        NED
  7            Pailhoriès H et al. (2014) \[[@b12-amjcaserep-20-406]\]        43/Male       Fever, delirium tremens                                                                            1 g of levofloxacin IV daily and 400 mg of oral doxycycline daily                                                                                                                                      NA                              NED
  8            Henao-Martínez et al. (2012) \[[@b13-amjcaserep-20-406]\]      40/Male       Fever                                                                                              Doxycycline 100 mg intravenously twice per day                                                                                                                                                         16 days                         NED
  9            Lee E et al. (2012) \[[@b6-amjcaserep-20-406]\]                48/Female     Fever                                                                                              IV moxifloxacin at a daily dose of 400 mg                                                                                                                                                              14 days                         NED
  10           Al Masalma M et al. (2011) \[[@b14-amjcaserep-20-406]\]        41/Female     Vertigo, coma headache, hemiparesis                                                                Doxycycline 200 mg/day                                                                                                                                                                                 12 weeks                        NED
  11           McCarthy KL and Looke DF (2008) \[[@b15-amjcaserep-20-406]\]   48/Male       Fever                                                                                              Gatifloxacin 400 mg IV daily and clindamycin 450 mg IV tds (Gatifloxacin was ceased after two weeks of therapy and clindamycin was changed to the oral formulation to complete a three-month course)   3 months                        NED
  12           McCarthy KL and Looke DF (2008) \[[@b15-amjcaserep-20-406]\]   17/Female     Fever                                                                                              IV gatifloxacin 400 mg daily for 1 month, then changed to oral moxifloxacin to complete a six-week course                                                                                              10 weeks                        NED
  13           Kupila L et al. (2006) \[[@b16-amjcaserep-20-406]\]            40/Male       Hematuria, urine retention and confusion                                                           Tetracycline                                                                                                                                                                                           NA                              NED
  14           House P et al. (2003) \[[@b17-amjcaserep-20-406]\]             40/Male       Headache, left facial weakness, nausea, afebrile                                                   Ciprofloxacin and metronidazole                                                                                                                                                                        6 weeks                         NED
  15           Douglas M et al. (2003) \[[@b18-amjcaserep-20-406]\]           17/Female     Fever, headache, photophobia, nausea, vomiting, right-sided hemiparesis and expressive dysphasia   Intravenous doxycycline 100 mg b.i.d. and clindamycin 800 mg t.i.d. then Doxycycline was changed to oral (100 mg b.i.d.) after 5 days, as was clindamycin (300 mg q.i.d.) after 7 days                 3 weeks                         NED
  16           Zheng X et al. (1997) \[[@b19-amjcaserep-20-406]\]             22/Female     Fever, left-sided weakness and numbness                                                            NA                                                                                                                                                                                                     NA                              NED
  17           Cohen M and Kubak B (1997) \[[@b20-amjcaserep-20-406]\]        18/Female     Fever, altered mental status                                                                       Initially IV doxycycline, ciprofloxacin, and erythromycin. Then IV chloramphenicol was added and IV erythromycin discontinued                                                                          NA                              NED
  18           McMahon D et al. (1990) \[[@b21-amjcaserep-20-406]\]           76/Male       Fever, unresponsive                                                                                NA                                                                                                                                                                                                     NA                              Death
  19           Madoff S et al. (1988) \[[@b22-amjcaserep-20-406]\]            11/Female     Fever                                                                                              Methacycline                                                                                                                                                                                           3 weeks                         Death after 3 weeks of therapy
  20           Payan D et al. (1981) \[[@b23-amjcaserep-20-406]\]             29/Male       Fever, loss of consciousness                                                                       4 g of IV tetracycline then changed to 4 g of IV erythromycin per day                                                                                                                                  2 weeks                         NED
  21           Paine T et al. (1950) \[[@b24-amjcaserep-20-406]\]             20/Male       Fever, headache, a stiff neck                                                                      Streptomycin                                                                                                                                                                                           NA                              NA

NED -- no evidence of disease; NA -- not available.
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